Anxiety may be early symptom of Alzheimer's disease in seniors | BMI, age predictive factors in lung cancer survival, study says | Study: MS drug rituximab shows lower rates of discontinuation
Curium - uniting IBA Molecular and Mallinckrodt Nuclear Medicine LLC.
Focusing on nuclear medicine.
ADVERTISEMENT
January 16, 2018
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
SIGN UP ⋅   FORWARD
Top Story
Anxiety may be early symptom of Alzheimer's disease in seniors
Researchers examined PET scans from 270 cognitively healthy adults ages 62 to 90 over five years and found that rising anxious-depressive symptoms were linked to higher amyloid-beta protein levels in the brain. The findings in The American Journal of Psychiatry suggest that anxiety symptoms may be an early indicator of preclinical Alzheimer's, said lead author Nancy Donovan.
New Atlas (1/14),  ScienceAlert (Australia & New Zealand) (1/15) 
LinkedIn Twitter Facebook Google+ Email
Clinical News & Research
BMI, age predictive factors in lung cancer survival, study says
Positive predictors of progression-free survival in lung cancer patients taking gemcitabine plus cisplatin are younger age and higher body mass index, researchers wrote in Thoracic Cancer. Response to initial therapy as well as higher BMI were predictive of overall survival.
Cancer Therapy Advisor (1/10) 
LinkedIn Twitter Facebook Google+ Email
Study: MS drug rituximab shows lower rates of discontinuation
A study in JAMA Neurology found Rituxan, or rituximab, was more effective and less likely to be discontinued than other medications in treatment-naïve patients with relapsing-remitting multiple sclerosis.
The Center for Biosimilars (1/10) 
LinkedIn Twitter Facebook Google+ Email
Industry Report
Morphotek's IND for tumor drug accepted for FDA review
The FDA accepted for review Eisai subsidiary Morphotek's investigational new drug application for MORAb-202, which combines farletuzumab with eribulin to treat patients with solid tumors that express folate receptor alpha.
PharmaBiz (India) (1/12) 
LinkedIn Twitter Facebook Google+ Email
FDA OKs Boston Scientific's nonopioid pain relief system
The FDA granted Boston Scientific approval for its Spectra WaveWriter Spinal Cord Stimulator System, which is intended to treat chronic pain using paresthesia-based therapy by producing a light, tingling sensation, and subperception therapy, which produces no sensation. The system provides relief of pain by delivering low pulses of electricity to the spinal cord.
Worcester Business Journal (Mass.) (1/11) 
LinkedIn Twitter Facebook Google+ Email
News from the Field
Program trains practitioners to support family caregivers
The Center to Advance Palliative Care and the Gary and Mary West Health Institute created training courses and resources health care practitioners can use to support caregivers of dementia patients. Experts said adopting best practices in caregiver support is a win-win for patients, caregivers and the health system.
Health Affairs Blog (1/11) 
LinkedIn Twitter Facebook Google+ Email
Health Policy
MedPAC recommends replacing MIPS with voluntary value program
MedPAC recommends replacing MIPS with voluntary value program
(Christopher Furlong/Getty Images)
The Medicare Payment Advisory Commission voted 14-2 to recommend the elimination of the Merit-based Incentive Payment System, with MedPAC policy analysts saying the system is too burdensome and complex for doctors and won't encourage higher-value care. MedPAC proposed replacing MIPS with a voluntary program, under which 2% of payments to clinicians would be withheld unless they agree to join an advanced payment model or choose to be evaluated as part of a larger group based on population-level quality, value and patient experience.
Modern Healthcare (tiered subscription model) (1/11),  Health Exec (1/11) 
LinkedIn Twitter Facebook Google+ Email
 
House task force drafts bills to cut opioid abuse
The House's Bipartisan Heroin Task Force has drafted more than a dozen bills intended to address prescription and illegal opioid abuse, including bills that would mandate prescriber education and licensing, electronic-only prescribing of prescriptions for controlled substances, and expanded access to medication-assisted treatment for certain populations, co-chair Tom MacArthur, R-N.J., said.
MedPage Today (free registration) (1/10) 
LinkedIn Twitter Facebook Google+ Email
Advancing Health Care
Health care systems, researchers put IBM's AI platform to good use
IBM Watson Health General Manager Deborah DiSanzo says IBM's artificial intelligence is already helping health care teams manage care for some 147,000 high-need patients. Pfizer and IBM Watson Health have worked together on immuno-oncology drug research, hospitals have used the platform to help guide cancer treatment decisions and IBM Watson's Clinical Trial Matching system is streamlining recruitment and enrollment for clinical trials, DiSanzo says.
The Motley Fool (1/12) 
LinkedIn Twitter Facebook Google+ Email
From SNMMI
Journal of Nuclear Medicine Technology to be indexed by Clarivate Analytics
The Journal of Nuclear Medicine Technology (JNMT) has been selected by Clarivate Analytics for inclusion in its Emerging Sources Citation Index. This coverage begins with 2017. Indexing in the ESCI should improve JNMT's visibility, and it provides a mark of quality -- both of which are good for authors. Read about it.
LinkedIn Twitter Facebook Google+ Email
Explore the fundamentals of the physics and technologies of nuclear medicine
Through concise, straightforward explanations and supporting graphics that bring abstract concepts to life, Basic Science of Nuclear Medicine -- the Bare Bone Essentials is an ideal tool for anyone looking for an introduction to the fundamentals of the physics and technologies of modern-day nuclear medicine. Order your copy today!
LinkedIn Twitter Facebook Google+ Email
Learn more about SNMMI:
SNMMI | News & Publications | Meetings | Education
Membership | Support Education/Research in Your Field
  
  
The reasonable man adapts himself to the world: the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man.
George Bernard Shaw,
playwright
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information